Onamelatucel-L

Summary

Onamelatucel-L (CHEMBL2108626) is a phase-3 clinical-stage cell; indicated across 1 condition including melanoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Cell
• Indications: 1 condition

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108626
Name	Onamelatucel-L
Type	Cell
Max phase	3

Also known as: Onamelatucel-l, ONAMELATUCEL-L

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
melanoma	3	MONDO:0005105	EFO:0000756

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).